Study of EYP-1901 in Patients With Diabetic Macular Edema (DME)

Inclusion Criteria: * Diagnosis of diabetes mellitus in the study eye, with disease onset any time prior to the Screening Visit * Previously treated with at least 1 intravitreal anti-VEGF in the last 6 months in the study eye at least 8 weeks prior to the Screening Visit. * BCVA letter score of 35 letters (20/200 Snellen equivalent) to 75 letters (20/32 Snellen equivalent) in the study eye at the Screening Visit and at Baseline (Day 1). Exclusion Criteria: * Any current or history of ocular disease other than DME * BCVA using ETDRS charts \<30 letters (20/250 Snellen equivalent) in the fellow eye. * Active ocular inflammation or active infection in either eye at Baseline (Day 1).